![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.
Lead Product(s): Edetate Calcium Disodium,Citric Acid
Therapeutic Area: Podiatry Product Name: Revye
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Lead Product(s): Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Elores
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2023
Details:
Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Lead Product(s): Edetate Calcium Disodium
Therapeutic Area: Pharmacology/Toxicology Product Name: Edetate Calcium Disodium-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
The net proceeds will be used to fund the company's pre-clinical and clinical development of its product candidates, including Mino-Lok® (minocycline), an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and CLABSIs.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 08, 2023
Details:
Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfactant.
Lead Product(s): Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kane Biotech
Deal Size: Undisclosed Upfront Cash: $0.5 million
Deal Type: Agreement April 20, 2023
Details:
The coactiv+™ (disodium EDTA) Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.
Lead Product(s): Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Salud Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2023
Details:
AB569 has been shown to kill multi-drug resistant (MDR) Gram-negative (G-) bacteria such as Pseudomonasaeruginosa, that is responsible for over half of all severe burn infections, and identified as a “major pathogen” by the Centers for Disease Control and Prevention.
Lead Product(s): Acidified nitrite,Edetate Calcium Disodium
Therapeutic Area: Infections and Infectious Diseases Product Name: AB569
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arch Biopartners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 24, 2021
Details:
Paper published in the journal PloS One demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumannii and Acinetobacter spp. bacteria.
Lead Product(s): Acidified nitrite,Edetate Calcium Disodium
Therapeutic Area: Infections and Infectious Diseases Product Name: AB569
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
The paper demonstrates key data on the synergistic effects of acidified sodium nitrite and EDTA (active ingredients of AB569) on destroying all bacteria
Lead Product(s): Sodium Nitrite,Edetate Calcium Disodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2020